TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI): Cluster-randomized Controlled Trial
Brief Summary: ST segment elevation myocardial infarction (STEMI) is a common presentation of heart attack constituting approximately 30% of all cases. Clinical guidelines around the world support the prolonged use of secondary preventative medications including aspirin, clopidogrel, statin, beta-blocker and angiotensin blockers with the highest recommendations. While in-hospital and discharge prescription rates are excellent, adherence to these essential life-saving medications is far less than ideal, even a few months following hospital discharge. The investigators plan to capitalize on the existing structure of the SMART-AMI project already underway in LHIN IV to undertake a randomized controlled trial evaluating a reminder sent on behalf of the interventional cardiologists, delivered by mail, at 1, 2, 5, 8, and 11-months post-discharge, reviewing the evidence for life-saving cardiac medications and urging long-term adherence to secondary preventative cardiac medications. This will be sent to the family physician and the patient, using audience-appropriate language. If the DERLA-STEMI project is accepted by physicians and patients, found to be both feasible and effective, then this simple and low-cost intervention will be studied in all patients with an abnormal coronary angiogram.


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention
C: Intervention Type: BEHAVIORAL; Name: Evidence summaries endorsed by local opinion leaders; Assigned to Arm(s): N/A
D: Arm Label: LTC Osteoporosis Toolkit Only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Educ sessions & LTC Osteoporosis toolkit; Type: ACTIVE_COMPARATOR; Interventions: Other: Educ sessions & LTC Osteoporosis toolkit | Intervention Type: OTHER; Name: Educ sessions & LTC Osteoporosis toolkit; Assigned to Arm(s): Educ sessions & LTC Osteoporosis toolkit

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy
Brief Summary: The purpose of this study is to compare the efficacy and safety of intravitreal ranibizumab injection versus low-fluence PDT in the treatment of chronic CSC.


Options:
A: Arm Label: Intravitreal Aflibercept Injection (x4); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Arm Label: Intravitreal Aflibercept Injection (x6); Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Aflibercept Injection | Intervention Type: DRUG; Name: Intravitreal Aflibercept Injection; Assigned to Arm(s): Intravitreal Aflibercept Injection (x4), Intravitreal Aflibercept Injection (x6)
B: Arm Label: Half-dose photodynamic therapy (PDT); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Half-dose photodynamic therapy (PDT) | Arm Label: Micropulse laser (ML) treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Micropulse laser (ML) treatment | Intervention Type: PROCEDURE; Name: Half-dose photodynamic therapy (PDT); Assigned to Arm(s): Half-dose photodynamic therapy (PDT) | Intervention Type: PROCEDURE; Name: Micropulse laser (ML) treatment; Assigned to Arm(s): Micropulse laser (ML) treatment
C: Arm Label: 50% dose PDT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PDT | Arm Label: 30% dose PDT; Type: EXPERIMENTAL; Interventions: Procedure: PDT | Intervention Type: PROCEDURE; Name: PDT; Assigned to Arm(s): 30% dose PDT, 50% dose PDT
D: Arm Label: Low-fluence PDT with Verteporfin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Verteporfin | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Intervention Type: DRUG; Name: Verteporfin; Assigned to Arm(s): Low-fluence PDT with Verteporfin | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): Ranibizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correlation Between Reoperation and Clinical Palpable Recurrence 3 Years After Ventral Hernia Repair
Brief Summary: The risk for recurrence after ventral hernia repair is often based on reoperation rates with short follow-up rather than recurrences identified by clinical examinations.

The purpose of current study is find the real incidence of recurrences 3 years after ventral hernia repair and to compare with the reoperation rate.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Interrupted sutures | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Continuous sutures | Intervention Type: PROCEDURE; Name: Interrupted sutures; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Continuous sutures; Assigned to Arm(s): B
B: N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mass closure | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Small stitches | Intervention Type: PROCEDURE; Name: Small stitches; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Mass closure; Assigned to Arm(s): 1
D: Arm Label: PDS II; Type: ACTIVE_COMPARATOR; Interventions: Device: PDS II | Arm Label: PDS plus; Type: EXPERIMENTAL; Interventions: Device: PDS plus | Intervention Type: DEVICE; Name: PDS plus; Assigned to Arm(s): PDS plus | Intervention Type: DEVICE; Name: PDS II; Assigned to Arm(s): PDS II

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to compare the decision making of hospitalized subjects having a verbal discussion about CPR compared to subjects using a video.


Options:
A: Arm Label: Telephone Genetic Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Genetic Counseling | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Telephone Genetic Counseling; Assigned to Arm(s): Telephone Genetic Counseling | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: Active Implementation phase; Type: OTHER; Interventions: Other: Uterine Fibroid Option Grid encounter patient decision aid (text only), Other: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures), Other: Uterine Fibroid Option Grid encounter patient decision aid (online) | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (text only); Assigned to Arm(s): Active Implementation phase | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures); Assigned to Arm(s): Active Implementation phase | Intervention Type: OTHER; Name: Uterine Fibroid Option Grid encounter patient decision aid (online); Assigned to Arm(s): Active Implementation phase
C: Arm Label: no intervention control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: experimental intervention group; Type: EXPERIMENTAL; Interventions: Other: video decision aid | Intervention Type: OTHER; Name: video decision aid; Assigned to Arm(s): experimental intervention group
D: Arm Label: Shared Decision Making/Brief Negotiated Interviewing; Type: OTHER; Interventions: Behavioral: Shared Decision Making | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making; Assigned to Arm(s): Shared Decision Making/Brief Negotiated Interviewing

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Seizure Detection and Automatic Magnet Mode Performance Study
Brief Summary: The purpose of this study is to confirm cardiac-based seizure detection in Cyberonics Model 106 VNS Therapy System.


Options:
A: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: Model 106 VNS Therapy System | Intervention Type: DEVICE; Name: Model 106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Device: PINS Vagus Nerve Stimualtor | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Device: PINS Vagus Nerve Stimualtor | Intervention Type: DEVICE; Name: PINS Vagus Nerve Stimualtor; Assigned to Arm(s): Control, Experimental
C: Arm Label: Model 106 VNS Therapy System; Type: OTHER; Interventions: Device: M106 VNS Therapy System | Intervention Type: DEVICE; Name: M106 VNS Therapy System; Assigned to Arm(s): Model 106 VNS Therapy System
D: Arm Label: Transcutaneous auricular vagal stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: Transcutaneous auricular non-vagal stimulation; Type: SHAM_COMPARATOR; Interventions: Device: ear vagus nerve stimulator | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ear vagus nerve stimulator; Assigned to Arm(s): Transcutaneous auricular non-vagal stimulation, Transcutaneous auricular vagal stimulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ReDIAL: A Telephone Brief Intervention for Injured Emergency Department Patients
Brief Summary: The goal of this study is to reduce impaired driving, risky driving and alcohol-related negative consequences among injured emergency department (ED) patients through a telephone brief intervention. This study will allow researchers to test a novel method of brief intervention that has the potential to be convenient and efficient mechanism to deliver an intervention to an at-risk population. Eligible patients will be consented in the ED, will receive an assessment and then will be randomized into one of two conditions: 1) telephone brief intervention or 2) a comparison control group with a home safety educational program. The participant will also receive an appointment for an initial telephone call. Both conditions will be provided over three telephone sessions: the initial call (immediately following randomization) and two booster calls at 2 weeks and 6 weeks after randomization. Participants will provide information about their alcohol use, alcohol-related injuries, impaired driving, and other driving related negative consequences at 4, 8, and 12 months post-randomization.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Patient-provider education; Type: EXPERIMENTAL; Interventions: Behavioral: Patient-provider education | Intervention Type: BEHAVIORAL; Name: Patient-provider education; Assigned to Arm(s): Patient-provider education
B: Arm Label: Brief Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement Therapy | Arm Label: Assessed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Contact Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Therapy; Assigned to Arm(s): Brief Intervention Group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Brief intervention | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Control group | Intervention Type: OTHER; Name: Brief intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): 2
D: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention | Intervention Type: BEHAVIORAL; Name: Brief intervention; Assigned to Arm(s): Counseling | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial
Brief Summary: Portal vein thrombosis (PVT) refers to an obstruction in the trunk of the portal vein. It can extend downstream to the portal branches, or upstream to the splenic and/or the mesenteric veins. The prevalence of PVT is 10-25% and incidence is about 16% in cirrhotic patients. Recent studies demonstrate that the presence of PVT is not only an independent predictor of failure to control active variceal bleeding and prevent variceal rebleeding, but also significantly associated with increased mortality in patients with liver cirrhosis.

However, in recent American Association of the Study of Liver Disease (AASLD) practice guidelines and Baveno V consensus, no treatment strategies in cirrhotic patients with PVT was clearly recommended due to the absence of randomized controlled trials.


Options:
A: Arm Label: Ligation and Cyanoacrylate Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ligation and Cyanoacrylate | Arm Label: Ligation plus Sclerotherapy and Cyanoacrylate Group; Type: EXPERIMENTAL; Interventions: Procedure: Ligation plus Sclerotherapy and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation and Cyanoacrylate; Assigned to Arm(s): Ligation and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation plus Sclerotherapy and Cyanoacrylate Group; Assigned to Arm(s): Ligation plus Sclerotherapy and Cyanoacrylate Group
B: Arm Label: Standard therapy + Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: Standard therapy + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Standard therapy + Simvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard therapy + placebo
C: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial
Brief Summary: Portal vein thrombosis (PVT) refers to an obstruction in the trunk of the portal vein. It can extend downstream to the portal branches, or upstream to the splenic and/or the mesenteric veins. The prevalence of PVT is 10-25% and incidence is about 16% in cirrhotic patients. Recent studies demonstrate that the presence of PVT is not only an independent predictor of failure to control active variceal bleeding and prevent variceal rebleeding, but also significantly associated with increased mortality in patients with liver cirrhosis.

However, in recent American Association of the Study of Liver Disease (AASLD) practice guidelines and Baveno V consensus, no treatment strategies in cirrhotic patients with PVT was clearly recommended due to the absence of randomized controlled trials.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B
B: Arm Label: TIPS treatment; Type: EXPERIMENTAL; Interventions: Procedure: TIPS treatment | Arm Label: Medical treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medical treatment | Intervention Type: PROCEDURE; Name: TIPS treatment; Assigned to Arm(s): TIPS treatment | Intervention Type: DRUG; Name: Medical treatment; Assigned to Arm(s): Medical treatment
C: Arm Label: Portacaval shunt; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Portacaval shunt | Arm Label: Sclerotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sclerotherapy | Intervention Type: PROCEDURE; Name: Portacaval shunt; Assigned to Arm(s): Portacaval shunt | Intervention Type: PROCEDURE; Name: Sclerotherapy; Assigned to Arm(s): Sclerotherapy
D: Arm Label: ET+NSBB; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ET+NSBB | Arm Label: TIPS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) | Intervention Type: PROCEDURE; Name: Transjugular intrahepatic portosystemic shunt (TIPS); Assigned to Arm(s): TIPS | Intervention Type: PROCEDURE; Name: ET+NSBB; Assigned to Arm(s): ET+NSBB

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Brief Summary: This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.


Options:
A: Intervention Type: DRUG; Name: imiquimod; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A
B: Arm Label: LDE225 200 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Arm Label: LDE225 800 mg; Type: EXPERIMENTAL; Interventions: Drug: LDE225 | Intervention Type: DRUG; Name: LDE225; Assigned to Arm(s): LDE225 200 mg, LDE225 800 mg
C: Arm Label: Vismodegib 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Vismodegib 150 mg | Intervention Type: DRUG; Name: Vismodegib 150 mg; Assigned to Arm(s): Vismodegib 150 mg
D: Arm Label: standard surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard surgery | Arm Label: Mohs; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mohs micrographic surgery | Intervention Type: PROCEDURE; Name: standard surgery; Assigned to Arm(s): standard surgery | Intervention Type: PROCEDURE; Name: Mohs micrographic surgery; Assigned to Arm(s): Mohs

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Bevacizumab for the Treatment of Patients With Low Vision Due to Neovascular Age-related Macular Degeneration
Brief Summary: The purpose of this study is to compare the effectiveness of intravitreal bevacizumab injection (IVBI) with respect to simple observation in patients with subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) presenting at baseline with best corrected visual acuity (BCVA) less than 20/200.


Options:
A: Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab
B: Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A
C: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
D: Arm Label: Bevacizumab 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab 1 | Arm Label: Bevacizumab 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab 1; Assigned to Arm(s): Bevacizumab 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Selenium Supplementation on CD4 + Cell Recovery, Viral Suppression, Morbidity and Quality of Life of HIV Infected Patients in Rwanda: a Prospective, Double-Blinded, Placebo-Controlled Trial
Brief Summary: Study Hypothesis: The addition of selenium supplementation to cotrimoxazole will improve CD4 counts, decrease opportunistic infections, decrease viral loads and delay the need for initiating antiretroviral therapy(ART) in Rwandan adult patients infected with HIV/ AIDS.


Options:
A: Arm Label: A: Broad spectrum micronutrients; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrients and antioxidants | Arm Label: B: Identical appearing multivitamins; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Multivitamins and minerals | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrients and antioxidants; Assigned to Arm(s): A: Broad spectrum micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamins and minerals; Assigned to Arm(s): B: Identical appearing multivitamins
B: Arm Label: Selenium; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Selenium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Selenium; Assigned to Arm(s): Selenium | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: multivitamin; Assigned to Arm(s): N/A
D: Arm Label: Active Drug (extended release niacin); Type: EXPERIMENTAL; Interventions: Drug: extended release niacin | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: extended release niacin; Assigned to Arm(s): Active Drug (extended release niacin)

Answer: B